Arai et al. evaluated the presence of FGFR2 fusions in a cohort of 102 cholangiocarcinoma patients observing that the fusions occurred exclusively in the intrahepatic cases with a prevalence of 13.6% [53]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.